Taro's first branded drug gets FDA trial nod (essential tremor)

Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) has obtained an Investigational New Drug exemption by the US Food and Drug Administration (FDA) for a clinical trial of its T2000 drug for the treatment of essential tremor.

The exemption was partly based on the results of Phase I and II clinical trials of the drug in Canada. Taro generally develops generic versions of existing drugs. T2000, a non-sedating barbiturate compound, is the company's first branded drug.

Essential tremor is involuntary trembling, most often in the arms, which occurs with movements, such as holding a glass to drink, or writing.
Source: Globes (extraits)

Anti Boycott Israel Blog: tremblements